Genomma Lab Internacional SAB de CV Class B LABB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LABB is a good fit for your portfolio.
News
-
Agreement Signed for Share Redemption in Marzam
-
Genomma Lab Internacional Announces Results for the First Quarter 2024
-
Genomma Lab Internacional S.A.B. de C.V. First Quarter 2024 Earnings Results Conference Call
-
GENOMMA LAB INTERNACIONAL ANNOUNCES SEVENTH DIVIDEND PAYMENT
-
Genomma Lab's ESG Rating Upgraded to A
-
Genomma Lab Internacional Reports Fourth Quarter & Full Year 2023 Results
-
EFFECTS OF ARGENTINA HYPERINFLATIONARY ACCOUNTING ON Q4 AND FULL YEAR 2023 RESULTS
Trading Information
- Previous Close Price
- MXN 16.57
- Day Range
- MXN 16.47–17.08
- 52-Week Range
- MXN 12.39–17.27
- Bid/Ask
- MXN 16.96 / MXN 17.05
- Market Cap
- MXN 16.14 Bil
- Volume/Avg
- 3.6 Mil / 3.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- 15.67
- Price/Sales
- 0.96
- Dividend Yield (Trailing)
- 4.73%
- Dividend Yield (Forward)
- 4.73%
- Total Yield
- 5.83%
Company Profile
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,975
- Website
- https://www.genommalab.com
Comparables
Valuation
|
Metric
|
LABB
|
BEVIDESA
|
GPROFUT
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.67 | 16.70 | 11.28 |
Price/Book Value | 1.61 | 4.14 | 2.33 |
Price/Sales | 0.96 | 0.51 | 1.42 |
Price/Cash Flow | 13.80 | — | 8.89 |
Price/Earnings
LABB
BEVIDESA
GPROFUT
Financial Strength
|
Metric
|
LABB
|
BEVIDESA
|
GPROFUT
|
|---|---|---|---|
Quick Ratio | 1.20 | 0.24 | 27.07 |
Current Ratio | 1.61 | 0.84 | 27.07 |
Interest Coverage | 2.87 | 1.90 | 10.76 |
Quick Ratio
LABB
BEVIDESA
GPROFUT
Profitability
|
Metric
|
LABB
|
BEVIDESA
|
GPROFUT
|
|---|---|---|---|
Return on Assets (Normalized) | 5.88% | 1.89% | 2.33% |
Return on Equity (Normalized) | 12.47% | 137.96% | 24.49% |
Return on Invested Capital (Normalized) | 10.39% | 11.46% | 19.40% |
Return on Assets
LABB
BEVIDESA
GPROFUT
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Xzkcfybdv | Btjrz | $76.2 Bil | |
MKKGY
| Merck KGaA ADR | Vywsxykns | Bgqrn | $70.9 Bil | |
HLN
| Haleon PLC ADR | Gsjfwjdvz | Lsyn | $37.8 Bil | |
VTRS
| Viatris Inc | Clwqzjhh | Myvq | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Hksgjsby | Bmmld | $12.7 Bil | |
CTLT
| Catalent Inc | Hstjhrhl | Vcjcf | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Tqhllvjc | Nxwm | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Dtxthwgm | Vzl | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Wcpltmv | Hfsjkmx | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Sbxvymsr | Dzh | $3.1 Bil |